Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial.

HFpEF Kidney disease SGLT2 inhibitor Weight

Journal

European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595

Informations de publication

Date de publication:
01 Apr 2024
Historique:
revised: 13 03 2024
received: 20 10 2023
accepted: 14 03 2024
medline: 1 4 2024
pubmed: 1 4 2024
entrez: 1 4 2024
Statut: aheadofprint

Résumé

Both low and high body mass index (BMI) are associated with poor heart failure outcomes. Whether BMI modifies benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in heart failure with preserved ejection fraction (HFpEF) requires further investigation. Using EMPEROR-Preserved data, the effects of empagliflozin versus placebo on the risks for the primary outcome (hospitalization for heart failure [HHF] or cardiovascular [CV] death), change in estimated glomerular filtration rate (eGFR) slopes, change in Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), and secondary outcomes across baseline BMI categories (<25 kg/m Empagliflozin treatment resulted in broadly consistent cardiac effects across the range of BMI in patients with HFpEF. SGLT2i treatment yields benefit in patients with HFpEF regardless of baseline BMI.

Identifiants

DOI: 10.1002/ejhf.3221 PMID: 38558521
pubmed: 38558521
doi: 10.1002/ejhf.3221
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : British Heart Foundation
ID : RE/18/6/34217
Pays : United Kingdom

Informations de copyright

© 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Packer M. The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range. Eur J Heart Fail 2019;21:156–162. https://doi.org/10.1002/ejhf.1377
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al.; EMPEROR‐Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–1461. https://doi.org/10.1056/NEJMoa2107038
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al.; PARAGON‐HF Investigators and Committees. Angiotensin‐neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609–1620. https://doi.org/10.1056/NEJMoa1908655
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al.; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–1392. https://doi.org/10.1056/NEJMoa1313731
Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al.; I‐PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456–2467. https://doi.org/10.1056/NEJMoa0805450
Shah SJ, Borlaug BA, Kitzman DW, McCulloch AD, Blaxall BC, Agarwal R, et al. Research priorities for heart failure with preserved ejection fraction: National Heart, Lung, and Blood Institute Working Group summary. Circulation 2020;141:1001–1026. https://doi.org/10.1161/CIRCULATIONAHA.119.041886
Reddy YNV, Rikhi A, Obokata M, Shah SJ, Lewis GD, AbouEzzedine OF, et al. Quality of life in heart failure with preserved ejection fraction: Importance of obesity, functional capacity, and physical inactivity. Eur J Heart Fail 2020;22:1009–1018. https://doi.org/10.1002/ejhf.1788
Adamson C, Kondo T, Jhund PS, de Boer RA, Cabrera Honorio JW, Claggett B, et al. Dapagliflozin for heart failure according to body mass index: The DELIVER trial. Eur Heart J 2022;43:4406–4417. https://doi.org/10.1093/eurheartj/ehac481
Reddy YNV, Lewis GD, Shah SJ, Obokata M, Abou‐Ezzedine OF, Fudim M, et al. Characterization of the obese phenotype of heart failure with preserved ejection fraction: A RELAX trial ancillary study. Mayo Clin Proc 2019;94:1199–1209. https://doi.org/10.1016/j.mayocp.2018.11.037
Savji N, Meijers WC, Bartz TM, Bhambhani V, Cushman M, Nayor M, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Fail 2018;6:701–709. https://doi.org/10.1016/j.jchf.2018.05.018
Siddiqi TJ, Anker SD, Filippatos G, Ferreira JP, Pocock SJ, Böhm M, et al. Health status across major subgroups of patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2023;25:1623–1631. https://doi.org/10.1002/ejhf.2831
Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial. Nat Med 2021;27:1954–1960. https://doi.org/10.1038/s41591‐021‐01536‐x
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al.; STEP‐HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069–1084. https://doi.org/10.1056/NEJMoa2306963
Rothman KJ. BMI‐related errors in the measurement of obesity. Int J Obes (Lond) 2008;32:S56–S59. https://doi.org/10.1038/ijo.2008.87

Auteurs

Naveed Sattar (N)

School of Cardiovascular and Metabolic Health, University of Glasgow, BHF Glasgow Cardiovascular Research Centre (GCRC), Glasgow, UK.
ORCID: 0000-0002-1604-2593

Javed Butler (J)

Baylor Scott and White Research Institute, Dallas TX and University of Mississippi, Jackson, MS, USA.

Matthew M Y Lee (MMY)

School of Cardiovascular and Metabolic Health, University of Glasgow, BHF Glasgow Cardiovascular Research Centre (GCRC), Glasgow, UK.

Josephine Harrington (J)

Division of Cardiology, Department of Medicine, Duke University, Durham, NC, USA.

Abhinav Sharma (A)

Division of Cardiology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.

Faiez Zannad (F)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, -Plurithématique 14-33 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Gerasimos Filippatos (G)

National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece.

Subodh Verma (S)

Division of Cardiac Surgery, St Michael's Hospital, Department of Surgery, and Pharmacology and Toxicology, University of Toronto, Toronto, ONT, Canada.

James L Januzzi (JL)

Massachusetts General Hospital and Baim Institute for Clinical Research, Boston, MA, USA.

João Pedro Ferreira (JP)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, -Plurithématique 14-33 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Cardiovascular R&D Centre-UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.
Heart Failure Clinic, Internal Medicine Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.

Stuart J Pocock (SJ)

Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.

Egon Pfarr (E)

Boehringer Ingelheim International GmbH, Ingelheim, Germany.

Anne P Ofstad (AP)

Boehringer Ingelheim Norway KS, Asker, Norway.
Oslo Diabetes Research Center, Oslo, Norway.

Martina Brueckmann (M)

Boehringer Ingelheim International GmbH, Ingelheim, Germany.
First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.

Milton Packer (M)

Baylor University Medical Center, Dallas, TX, USA.

Stefan D Anker (SD)

Department of Cardiology (CVK) of German Heart Center Charité; German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany.

Classifications MeSH